Amani Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Amani Therapeutics, Inc. - overview
Established
2025
Location
New York, NY, US
Primary Industry
Biotechnology
About
Amani Therapeutics is a US-based biotech firm focused on developing innovative therapies for serious neuropsychiatric disorders, particularly targeting treatment-resistant schizophrenia with its lead product AM-01. Amani Therapeutics, founded in 2025 in New York, US, is dedicated to addressing neuropsychiatric disorders through the development of advanced therapies. In November 2025, Amani Therapeutics raised USD 31. 12 million in series A funding led by RTW Investments.
Amani Therapeutics specializes in developing innovative therapies for serious neuropsychiatric disorders, focusing on its lead product, AM-01. This therapy is a fixed-dose combination of clozapine and a novel chemical entity designed to maximize efficacy for treatment-resistant schizophrenia while reducing the risk of severe neutropenia. The company aims to improve patient outcomes by facilitating effective treatment options for psychiatric illnesses and collaborates with healthcare providers and pharmacies to ensure access to its products. Amani Therapeutics has secured USD 25.
00 mn in Series A funding to advance the development of AM-01. Revenue generation is expected through partnerships with healthcare institutions and distribution agreements with pharmaceutical wholesalers. This B2B model allows healthcare providers to purchase AM-01 through established channels, ensuring availability for patients suffering from treatment-resistant schizophrenia, thus supporting future growth in revenue driven by the product's therapeutic potential. Amani Therapeutics plans to use the recent Series A funding to enhance the clinical development of AM-01, which is aimed at addressing critical needs in neuropsychiatric care.
The company is also looking to expand into international markets where treatment-resistant schizophrenia is prevalent, leveraging its collaborations to facilitate this growth. The funding will support ongoing research and development efforts, positioning AM-01 for a potential launch in key markets, enhancing accessibility to its innovative therapies.
Current Investors
RTW Investments
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.amanitx.com/
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.